Skip to main content

Vaccines
for the Future

Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, employs proprietary 1c-SApNP® platform technology developed by Dr. Jiang Zhu of Scripps Research to develop and commercialize prophylactic vaccines for the most challenging infectious diseases

Our Vision

To become a global leader in the vaccine industry and offer vaccine solutions for unmet public health needs

Our Mission

Working to solve the world's infectious disease threats by combining rational antigen design and protein engineering to create virus-like particle vaccines

Key Milestones
  • 2013

    Dr. Jiang Zhu started his lab at The Scripps Research Institute (TSRI) working on antibody discovery and rational vaccine design.

  • 2018

    Uvax Bio was founded, utilizing proprietary 1c-SApNP® platform technology developed by Dr. Jiang Zhu.

  • 2020

    1c-SApNP® vaccine construct design was finalized for HIV-1.  High-yield research cell bank (RCB) development started.

  • 2022

    HIV-1 vaccine candidates in preparation for Phase 1 trials. Three new vaccine assets currently in RCB development.

  • 2023

    HIV-1 Preclinical data published. The National Institutes of Health (NIH) has agreed to sponsor a Phase 1 clinical trial.